Repaglinide-d 5 is deuterium labeled Repaglinide. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus[1].
性状
Solid
体外研究(In Vitro)
Repaglinide reduces postprandial glucose levels by enhancing the early phase of insulin secretion and increasing the total amount of insulin secreted. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Wang LC, et al. Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus.Medicine (Baltimore). 2018 Sep;97(38):e12476.
[1]. Wang LC, et al. Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus.Medicine (Baltimore). 2018 Sep;97(38):e12476.